Stabilizing alkylglycoside compositions and methods thereof
View Patent ↗The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example interferons, such as interferon-alpha, interferon-beta, interferon-gamma, and variants thereof.
1. A liquid pharmaceutical composition for increasing the stability, reducing aggregation or reducing immunogenicity of interferon comprising:
a) interferon; and
b) a stabilizing agent,
wherein the stabilizing agent is dodecyl-β-D-maltoside, and wherein the composition is formulated for systemic delivery.
2. The composition of claim 1 , further comprising a buffering agent.
3. The composition of claim 1 , wherein the interferon is interferon-alpha or a variant thereof.
4. The composition of claim 1 , wherein the alkylglycoside has a critical micelle concentration (CMC) of less than about 1 mM.
5. The composition of claim 4 , wherein the alkylglycoside has a CMC of less than about 0.5 mM.
6. The composition of claim 1 , further comprising a mucosal delivery-enhancing agent selected from the group consisting of an aggregation inhibitory agent, a charge-modifying agent, a pH control agent, a degradative enzyme inhibitory agent, a mucolytic or mucus clearing agent, a chitosan, and a ciliostatic agent.
7. The composition of claim 6 , wherein the mucosal delivery-enhancing agent is a chitosan.
8. The composition of claim 6 , wherein the mucosal delivery-enhancing agent is a ciliostatic agent.
9. The composition of claim 6 , further comprising benzalkonium chloride or chloroethanol.
10. The composition of claim 1 , further comprising a membrane penetration-enhancing agent selected from the group consisting of a surfactant, a bile salt, a phospholipid additive, a mixed micelle, a liposome, a carrier, an alcohol, an enamine, a nitric oxide donor compound, a long-chain amphipathic molecule, a small hydrophobic penetration enhancer, a sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin or beta-cyclodextrin derivative, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an N-acetylamino acid or salt thereof, an enzyme degradative to a selected membrane component and any combination thereof.
11. The composition of claim 1 , further comprising a modulatory agent of epithelial junction physiology.
12. The composition of claim 1 , further comprising a vasodilator agent.
13. The composition of claim 1 , further comprising a selective transport-enhancing agent.
14. The composition of claim 1 , wherein the composition is stable for at least one month when stored at temperatures from about 25 to 37 degrees Celsius.
15. The composition of claim 1 , wherein the composition is stable for at least two months.
16. The composition of claim 1 , wherein the composition is stable for at least one year when stored at about 4 degrees Celsius.
17. The composition of claim 1 , wherein the stability of the composition is determined by determining the bioactivity of the interferon in an in vivo or in vitro assay.
18. The composition of claim 1 , wherein the composition further comprises a bulking agent selected from the group consisting of albumin, collagen, alginate, and mannitol.
19. The composition of claim 1 , wherein the interferon is interferon-beta or a variant thereof.
20. The composition of claim 1 , wherein the interferon is interferon-gamma or a variant thereof.
21. A pharmaceutical composition for increasing the stability, reducing aggregation or reducing immunogenicity of interferon comprising:
a) interferon; and
b) a stabilizing agent,
wherein the stabilizing agent is dodecyl-β-D-maltoside, and wherein the composition is in a lyophilized form.
22. The composition of claim 21 , wherein the interferon is interferon-beta or a variant thereof.
23. The composition of claim 21 , wherein the interferon is interferon-gamma or a variant thereof.
24. The composition of claim 21 , wherein the interferon is interferon-alpha or a variant thereof.
25. The composition of claim 21 , wherein the lyophilized composition retains greater than 50% biological activity upon reconstitution.
26. The composition of claim 21 , wherein the composition is stable for at least one month when stored at temperatures from about 25 to 37 degrees Celsius.
27. The composition of claim 21 , wherein the composition is stable for at least two months.
28. The composition of claim 21 , wherein the composition is stable for at least one year when stored at about 4 degrees Celsius.
29. The composition of claim 21 , wherein the lyophilized composition further comprises a bulking agent selected from the group consisting of albumin, collagen, alginate, and mannitol.
30. The composition of claim 21 , wherein the lyophilized composition is reconstituted prior to administering to a mammalian subject.
31. A pharmaceutical composition for increasing the stability, reducing aggregation or reducing immunogenicity of interferon comprising:
a) interferon; and
b) a stabilizing agent,
wherein the stabilizing agent is an alkylsaccharide consisting of dodecylβ-D-maltoside.
32. The composition of claim 31 , wherein the interferon is interferon-beta or a variant thereof.
33. The composition of claim 31 , wherein the interferon is interferon-gamma or a variant thereof.
34. The composition of claim 31 , wherein the interferon is interferon-alpha or a variant thereof.